2025 Thessaloniki, Greece
Meeting information
Programme Item
Presenter
Abstract Category
Search Abstract
II-49 Sylvaine Galiegue
Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies
Wednesday 15:35-17:00